NCT04128917

Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT

A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Triple Therapy With Tegoprazan, Amoxicillin and Clarithromycin in H. Pylori Positive Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: HK inno.N Corporation · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

Detailed description

A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Tegoprazan	Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral
DRUG	RAPAE01	RAPAE01/Clarithromycin/Amoxicillin BID peroral

Timeline

• Start date: 2020-01-21
• Primary completion: 2020-12-21
• Completion: 2021-01-29
• First posted: 2019-10-16
• Last updated: 2021-05-12

Locations

1 site across 1 country: South Korea